Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03474718 · ClinicalTrials.gov registry record · Early Phase 1
Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia
A Early Phase 1 study, sponsored by Wake Forest University Health Sciences.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 16
- Enrollment target
NCT03474718 is a Early Phase 1 study that has not yet begun recruiting, run by Wake Forest University Health Sciences. The registered enrollment target is 16 participants.
The verdict
NCT03474718, a Early Phase 1 study, has not yet begun recruiting, sponsored by Wake Forest University Health Sciences.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The study team will assess the efficacy of platelet-rich plasma therapy, a special blood product which is from the participant's own body, in the treatment of androgenic alopecia (also known as male pattern hair loss) in females.
Interventions
- BIOLOGICAL Platelet-rich Plasma Left Side
- BIOLOGICAL Platelet-rich Plasma Right Side
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2026-07 |
| Est. Completion | 2027-07 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03474718
The ClinicalTrials.gov registry entry for NCT03474718 describes a study currently listed as not yet recruiting, categorized as Early Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Platelet-rich Plasma Left Side is the first listed.
NCT03474718 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03474718 about?
NCT03474718 is a clinical study titled "Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia". The study team will assess the efficacy of platelet-rich plasma therapy, a special blood product which is from the participant's own body, in the treatment of androgenic alopecia (also known as male pattern hair loss) in females.
What is the current status of trial NCT03474718?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 16 participants. The study started on 2026-07. Estimated completion is 2027-07.
What interventions are being tested in trial NCT03474718?
The interventions under investigation include: Platelet-rich Plasma Left Side (BIOLOGICAL), Platelet-rich Plasma Right Side (BIOLOGICAL).
Who is sponsoring clinical trial NCT03474718?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.